Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

1.36
EUR
0.00
(0.00%)
-1.22EPS
Apr 01Next Earn
Tenax Therapeutics, Inc.
GETTEX:YBO0
(Gettex)

Recent

price

1.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
8,954.14
9,222.98
20,567.32
331.87
56.13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-290,230.44
-349,164.67
-172,897.85
-29,132.41
-16,038.51
- -
-50,027.23
-10,022.32
-5,967.95
-2,167.97
-1,520.75
-2,525.22
-600.72
-31.04
-1.15
-1.34
-1.38
Basic EPS, GAAP
-246,307.81
-189,861.22
-84,555.57
-10,656.75
-11,108.23
- -
-18,079.94
-13,769.9
-2,323.65
-1,952.42
-1,431.98
-844.59
-619.37
-23.76
-0.97
-0.91
-1.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-103,458.97
-7,689.91
-29,633.95
95,270.53
80,215.3
2.15
19,522.71
10,070.14
4,966.77
895.44
586.48
269.43
52.11
27.15
26.89
10.42
2.39
Book Value per Share
-122,902.06
-27,089.27
-45,045.58
55,885.65
42,327.94
2.15
19,522.71
10,070.14
4,966.77
895.44
586.48
269.43
52.11
27.15
26.89
10.42
2.39
Tangible Book Value per Share
- -
- -
- -
- -
- -
28
- -
- -
- -
- -
- -
- -
- -
- -
15
39
48
Basic Weighted Avg Shares
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-3,183.08
-1,973.49
-400.4
-5,753.25
-27,963.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-10
-16
-9
-20
-14
- -
-44
-9
-7
-8
-10
-32
-11
-8
-18
-53
-66
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,241.3
-3,785.81
-763.01
-6,768.3
-28,571.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
- -
- -
56
13
16
7
7
12
4
5
4
1
8
92
97
109
Working Capital
4
1
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-4
- -
-2
83
70
60
17
9
12
4
5
4
1
8
92
97
109
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-18.37
- -
-113.26
-67.94
-136.97
-108.01
-234.61
-732.21
-385.12
-160.8
-35.17
-55.64
-64.2
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
32
46
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
123
122
117
Cash, Cash Equivalents & STI
119
118
114
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
8
Payables & Accruals
8
7
7
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
127.83%
282.19%
5.52%
Free Cash Flow
- -
53.27%
141.71%
Net Income, GAAP
- -
92.11%
198.82%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.12
-1.83
-0.19
-0.18
-1.15
2025
-0.28
-0.27
-0.4
-0.38
-1.34
2026
-0.35
-0.35
-0.31
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Tenax Therapeutics, Inc. (Nasdaq: TENX) is a Phase 3 development-stage pharmaceutical company focused on developing novel therapies for cardiopulmonary diseases, particularly pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company develops TNX-103, an oral formulation of levosimendan that has completed Phase 2 trials for PH-HFpEF; TNX-201, an oral enteric-coated imatinib for pulmonary arterial hypertension (PAH); and earlier-stage candidates including TNX-101 and TNX-102 for related pulmonary hypertension indications. Founded in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates primarily in the United States with a small team of experts guiding its clinical programs targeting unmet needs in cardiovascular and pulmonary care. In August 2024, the company closed an oversubscribed $100 million private placement led by BVF Partners LP with participation from Venrock Healthcare Capital Partners, Vivo Capital, Janus Henderson Investors and others to fund the ongoing LEVEL Phase 3 trial of TNX-103 and initiate a second Phase 3 study in 2025, accelerating its path to NDA submission; this followed a $25 million private placement with RTW Investments in March 2025 to support clinical trials and operations.

Company News

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • TENX Investor Alert: Tenax Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

  • INVESTOR REMINDER: Berger Montague Notifies Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors of a Class Action Lawsuit and Deadline

  • Kaplan Fox Encourages Tenax Therapeutics, Inc. (TENX) Investors to Contact the Firm Before the Deadline on December 28, 2026 for a Leadership Role

  • ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • TENX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

  • ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • ROSEN, A TOP RANKED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • Kaplan Fox Advises Tenax Therapeutics, Inc. (TENX) Investors to Act Before the Lead Plaintiff Deadline on December 28, 2026

  • Did You Lose Money on Tenax Therapeutics, Inc. Stock? Faruqi & Faruqi, LLP Reminds Investors of December 28, 2026 Lead Plaintiff Deadline in Securities Class Action After 89.77% Share Price Decline

  • ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • DEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd.

  • TENX Investor Alert: Johnson Fistel Encourages Tenax Therapeutics, Inc. Investors to Contact the Firm Ahead of December 28, 2026 Lead Plaintiff Deadline

  • Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX

  • TENX Deadline Alert: SueWallSt Reminds Tenax Therapeutics, Inc. (TENX) Investors of Securities Class Action Deadline on December 28, 2026

  • TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

  • Deadline Alert: Tenax Therapeutics, Inc. Investors Have Until December 28, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

  • ROSEN, A TOP-RANKED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX